Conclusions
BPD, death, NDI
SECONDARY
In this secondary analysis for heterogeneity of treatment effect in infants enrolled in the NICHD NRN Hydrocortisone Trial, baseline risk for grades 2 or 3 BPD or death did not modify the treatment effect of hydrocortisone for either observed grades 2 or 3 BPD or death or moderate or severe NDI or death. Similar analyses of other randomized clinical trials of corticosteroid exposure may be warranted to more precisely evaluate whether specific subpopulations of extremely preterm infants are more likely to benefit from or be harmed by systemic hydrocortisone treatment.